The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Abacavir/Lamivudine Rowex 600 mg/300 mg film-coated tablets

600 mg/300 milligram(s) Film-coated tablet

Rowex LtdPA0711/251/001

Main Information

Trade NameAbacavir/Lamivudine Rowex 600 mg/300 mg film-coated tablets
Active SubstancesLamivudine
Strength600 mg/300 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderRowex Ltd
Licence NumberPA0711/251/001

Group Information

ATC Code


Withdrawn Date19/10/2021
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Educational Materials - Patient

« Back